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Abstract
Objective: Clinical and immunological data about HIV in older adults from low and middle income countries is
scarce. We aimed to describe differences between younger and older adults with HIV starting antiretroviral therapy in
two low–income African countries.
Methods: Setting: HIV clinics in Uganda and Zimbabwe. Design: Secondary exploratory cross-sectional analysis of
the DART randomized controlled trial. Outcome Measures: Clinical and laboratory characteristics were compared
between adults aged 18-49 years (younger) and ≥ 50 years (older), using two exploratory multivariable logistic
regression models, one with HIV viral load (measured in a subset pre-ART) and one without.
Results: A total of 3316 eligible participants enrolled in DART were available for analysis; 219 (7%) were ≥ 50 years
and 1160 (35%) were male. Across the two adjusted regression models, older adults had significantly higher systolic
blood pressure, lower creatinine clearance and were consistently less likely to be females compared to younger
adults with HIV. Paradoxically, the models separately suggested that older adults had statistically significant (but not
clinically important) higher CD4+ cell counts and higher plasma HIV–1 viral copies at initiation. Crude associations
between older age and higher baseline hemoglobin, body mass index, diastolic blood pressure and lower WHO
clinical stage were not sustained in the adjusted analysis.
Conclusions: Our study found clinical and immunological differences between younger and older adults, in a cohort
of Africans starting antiretroviral therapy. Further investigations should explore how these differences could be used
to ensure equity in service delivery and affect outcomes of antiretroviral therapy.
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Introduction
Globally, the proportion of older adults is increasing [1]. In
regard to HIV, persons 50 years and above are considered
“older adults” [2–4]. In this fourth decade of the AIDS epidemic,
the HIV–infected population is growing older primarily due to
successful antiretroviral therapy (ART) but also among those
newly diagnosed [5]. Reports from high-income countries show
that adults over 50 years doubled from 10-15% of the HIV–
infected population in 2005, to about 30% by 2010 [6,7]. This
phenomenon has also been observed in sub–Saharan Africa
[8].
Older adults with HIV present with different clinical,
immunological and even social profiles which potentially
influence outcomes [9–14]. For example, adults aging with HIV
experience multiple co-morbidities with resultant poly-
pharmacy, may respond differently to ART, and are commonly
stigmatized or socially isolated. However, existing evidence on
aging and HIV/AIDS is largely from high income countries. The
few publications from sub–Saharan Africa do not provide as
much information regarding some of the co-morbidities such as
Hepatitis B and C co-infection, renal dysfunction, hypertension
or viral loads [8,15–17]. In order to explore these issues of HIV
patients initiating ART, we compared clinical and
immunological differences between older (≥ 50 years) and
younger (18-49 years) adults starting ART in Uganda and
Zimbabwe which are low income countries in sub–Saharan
Africa.
Methods
Study design, procedures and setting
In this secondary data analysis, we used information from
the Development of Anti-Retroviral Therapy in Africa (DART)
trial. DART was an open randomized trial comparing two
management strategies for monitoring ART, and details of the
methods have been reported elsewhere [18]. Briefly, 3316
eligible symptomatic (WHO stage 2–4) HIV–infected adults
(≥18 years) with CD4+ counts less than 200 cells/ml who
reported no previous ART apart from to prevent mother–to–
child transmission, were enrolled from three centres in Uganda
and one centre in Zimbabwe from 15 January 2003 to 28
October 2004. Viral loads (n=968 at baseline) were done
retrospectively using stored samples, and were not used for
clinical management.
Statistical analysis
We conducted this exploratory analysis to identify variables
that differed significantly between the younger and older adults
with HIV (18-49 versus >50 years) at enrollment into ART care.
We summarized clinical measures (sex, systolic and diastolic
blood pressure, body mass index, WHO clinical stage),
laboratory results (hemoglobin, CD4+ cell counts, viral load,
creatinine, alanine and aspartate amino–transferase),
infectious (hepatitis B surface antigen and anti-hepatitis C) and
non-communicable (hypertension, overweight and obesity) co-
morbidities using frequencies, percentages and measures of
central tendency as appropriate. We referred to World Health
Organization cut offs for hypertension, overweight and obesity.
We computed creatinine clearance using the Cockcroft–Gault
equation [19]. We then explored associations between age
(18-49 versus >50 years) and each variable using logistic
regression. Tests were two–sided and considered significant if
P<0.05. Variables with P<0.2 in univariate analysis were
included in a multivariable logistic regression model to estimate
the adjusted Odds Ratios (aOR) and their 95% confidence
intervals (95% CI). We excluded creatinine and body mass
index (BMI) from adjusted analyses due to their significant
correlation with creatinine clearance (r2 =-0.6 and r2=0.33,
respectively, both p<0.0001). Because not all participants had
HIV-1 RNA measures taken, we employed two adjusted
regression models. Model 1 incorporated all variables eligible
for inclusion from the univariate analysis (P<0.2), except viral
load, creatinine and BMI (as above). An interaction term
between sex and hemoglobin was included since a previous
analysis showed that women had significantly lower
hemoglobin in DART [20]. Model 2 included viral load
measurements into model 1 in the subgroup of participants with
pre-ART HIV-1 RNA levels available.
Ethical considerations
The DART trial was approved by ethics committees in
Uganda, Zimbabwe and United Kingdom. This secondary
analysis was approved by the Joint Clinical Research Centre
Institutional Review Board in Uganda. Written informed consent
was obtained from each enrolled participant for trial
participation and provision and analysis of data.
Results
Baseline characteristics
3316 eligible participants were included in the DART trial.
Overall, the majority were females (65%) and the mean age
(SD) was 37.6 years (7.8) with 219 (7.0%) of the participants
aged ≥ 50 years or older. Only 968 (29.2%) participants had
baseline viral loads measured and the mean (SD) was 5.4 (0.7)
log 10 copies/mL. Further details are in table 1.
Prevalence of co-morbidities
The prevalence of systolic and diastolic hypertension was
21.3% and 19.0% for older adults; and 9.2% and 3.5% for
younger adults with HIV (both, p<0.001) respectively. 24.0% of
older adults and 14.8% younger adults were either overweight
or obese (p<0.001). The prevalence of anti-hepatitis C virus
sero-positivity was 3.7% and 2.3% for older and younger adults
respectively (p=0.17); whilst that for hepatitis B surface antigen
was 5.6% and 9.6% respectively (p=0.05). Finally, the
proportion of having at least two co-morbidities (communicable
and or non-communicable) was 11.4% and 5.1% among older
and younger adults respectively (p<0.001) (Data not tabulated).
Differences between older (≥50 years) and younger
(18-49 years) adults with HIV and AIDS
In the adjusted analysis without viral load data (table 2,
model 1), there were significantly fewer females among older
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adults (aOR: 0.03, 95% CI: 0.00-0.19, p<0.001). Older adults
had significantly higher systolic blood pressure (aOR: 1.05,
95% CI: 1.03-1.06, p<0.001), higher CD4+ cell counts (aOR:
1.00, 95% CI: 1.00-1.01, p=0.009) and lower creatinine
clearance (OR: 0.97, 95% CI: 0.96-0.97, p<0.001). The
association between higher hemoglobin and older age
remained significant among females, sustaining the effect
modification even after adjustment (heterogeneity p=0.003).
Using viral load in the sub-population where this was
available (table 2, model 2) the association between older age
and higher systolic blood pressure and lower creatinine
clearance was maintained (p<0.001). Additionally, females
were significantly fewer in the older age group (p=0.025). The
effect modification of sex in the association between older age
and higher hemoglobin among females also remained
significant (heterogeneity p=0.049). However, higher viral load
(p=0.005) remained independently associated with older adults
infected with HIV instead of CD4+, which no longer provided
independent information (p=0.4).
Discussion
HIV and aging is an inevitable global health challenge today
[21]. The world population is aging to the extent that chronic
diseases are on the rise and stretching health care budgets,
particularly in sub–Saharan Africa [22]. Still, in low income
countries like Uganda and Zimbabwe, the existing high burden
of infectious diseases including HIV/AIDS, tuberculosis and
malaria, presents a dual challenge to the health systems [22].
Therefore, innovative strategies to integrate care for older
adults are urgently needed and understanding the
Table 1. Characteristics at ART initiation stratified by age < 50 years and age ≥ 50 years.
Variable N = 3316 18-50 years ≥ 50 years P-Value
n (%)  3097 (93) 219 (7)  
Age (years, mean, SD) 37.6 (7.8) 36.3 (6.3) 55.1 (4.4) P<0.001
Sex     
Male (%) 1160 (3,5) 1054 (90.9) 106 (9.1) P<0.001
Female (%) 2156 (65) 2043 (94.8) 113 (5.2)  
BMI     
mean (SD) 21.7 (3.8) 21.6 (3.8) 22.5 (3.9) P<0.001
Blood Pressure (mm Hg)     
Systolic, mean (SD) 110.6 (14.7) 109.9 (13.9) 120.9 (20.2) P<0.001
Diastolic, mean (SD) 72.3 (11.1) 71.9 (10.8) 77.9 (13.6) P<0.001
WHO Clinical Stage (%)     
II 673 (20) 620 (92) 53 (8) P=0.077
III 1864 (56) 1737 (93) 127 (7)  
IV 779 (24) 740 (95) 39 (5)  
CD4+ (cells/µL)     
median (IQR) 86 (81–139) 85 (30–138) 92 (45–147) P=0.222
Viral Load (log10 cp/mL)    
mean (SD) 5.4 (0.7) 5.4 (0.7) 5.7 (0.5) P=0.003
Hemoglobin (g/dL)     
mean (SD) 11.5 (1.7) 11.5 (1.8) 11.7 (1.5) P=0.078
Creatinine (mg/dL)     
mean (SD) 0.91 (0.27) 0.90 (0.27) 0.98 (0.26) P<0.001
ALT (mmol/L)     
median (IQR) 25 (18–36) 25 (18–36) 23 (17–33) P=0.008
AST (mmol/L)     
median (IQR) 34 (26–48) 34 (26–48) 34 (25–44) P=0.895
Hepatitis B virus     
pos (%) 302 (9.3) 290 (96) 12 (4) P=0.053
neg (%) 2,950 (90.7) 2,747 (93.1) 203 (6.9)  
Hepatitis C virus     
pos (%) 77 (2.4) 69 (89.6) 8 (10.4) P=0.177
neg (%) 3,176 (97.6) 2,969 (93.5) 207 (6.5)  
Abbreviations: ALT – Alanine transaminase; AST – Aspartate transaminase; BMI – Body Mass Index; CD4+ – Cluster of Differentiation; CI – Confidence Interval; cp –
copies; IQR – Inter Quartile Range; neg – negative; OR – Odds Ratio; pos – positive; SD – Standard Deviation; WHO – World Health Organization; dL – deciliter; g – grams;
Hg – mercury; mmol – millimols; mL − milliliter; mm – millimeters; µL – microliter
* n=968 (< 50 years n = 912; > 50 years n = 56).
doi: 10.1371/journal.pone.0076158.t001
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characteristics of such a population is a sound starting point
[3,23].
Our study explored clinical and immunological differences
associated with older adults with HIV and AIDS starting
antiretroviral therapy. Whilst such data are largely from the high
income settings, few studies from sub–Saharan Africa have
reported laboratory biomarkers for adults with HIV and AIDS
older than 50 years. In the DART cohort, older adults had
significantly higher systolic blood pressure, lower creatinine
clearance, higher CD4+ cell counts, and higher plasma HIV–1
RNA viral copies/mL, compared to younger adults in the
multivariable regression models. Women were also
proportionately less well represented, despite making up the
majority of the trial population.
That older adult females were significantly fewer in
Zimbabwe and Uganda raises concern of gender inequity in
accessing HIV and AIDS care in low income countries. This
finding is corroborated in a recent study by Negin and
colleagues who reported that older adults in Malawi were more
likely to be male [24]. Indeed, older adult females with HIV are
probably widowed, neglected and lack resources or the social
fabric to reach HIV care and treatment services [25].
Alternatively, this could be a cohort effect depicting earlier
mortality among females with HIV and AIDS compared to
males such that, only those who survived accessed care.
However, given results from a recent systematic review that
men have worse outcomes even on ART, and that majority of
trial participants were women, this is quite unlikely [26].
Noteworthy, this could be a consequence of earlier sexual
debut associated with riskier sexual behavior and probably HIV
infection in females compared to males [27,28]. On the
contrary, older men may be more sexually active and with
multiple partners, thus increasing their risk of HIV than older
women [29]. Possibly, the DART recruitment procedures and
avenues could have systematically excluded older women.
Regardless of the underlying reason, our findings highlight the
importance of HIV treatment and care interventions in Africa
mainstreaming gender issues to improve access, even for
females older than 50 years who are naturally no longer
reproductive. Notably, menopause leads to changes in immune
response, vaginal or cervical epithelium and secretions that
may influence HIV transmission or progression among those
who remain sexually active [30–32]. Hence, such programmes
could consider expanding their maternal and child health
paradigm to include women’s health. In relation to this, older
adult females had consistently higher hemoglobin levels
compared to the younger reproductive age group (potentially
due to child-bearing in the latter) which underscores the point
that their clinical needs are indeed different.
It is certainly not surprising that older adults had higher
systolic blood pressure and lower creatinine clearance. Older
age is characterized by general decline in organ (renal)
function, narrowing and hardening of blood vessels [33–35].
However, recent evidence from Europe and America suggests
that there is an excess risk of morbidity and mortality due to
cardiovascular and renal diseases among HIV–infected
Table 2. Logistic regression model for characteristics at ART initiation for adults who were older (≥ 50 years) compared to
younger ones (18-50 years) (N=3316).
Variable Unadjusted §Adjusted Model 1 (n=3184) Ω Adjusted Model 2 (n=943)
 OR 95% CI p-value aOR 95% CI p-value aOR 95% CI p-value
Female 0.55 0.42-0.72 <0.001 0.03 0.00-0.19 <0.001 0.01 0.00-0.38 0.016
BMI (Kg/M2) 1.06 1.02-1.09 0.001 – – – – – –
Syst. BP (mm Hg) 1.04 1.03-1.05 <0.001 1.05 1.03-1.06 <0.001 1.06 1.03-1.09 <0.001
Diast. BP (mm Hg) 1.04 1.03-1.06 <0.001 0.99 0.98-1.02 0.728 1.00 0.96-1.03 0.597
α WHO stage 0.79 0.64-0.97 0.027 0.98 0.78-1.24 0.878 1.19 0.56-2.56 0.649
CD4+ (cells/µL) 1.00 1.00-1.01 0.009 1.00 1.00-1.01 0.034 1.00 1.00-1.01 0.359
*VL (log 10 cp/mL) 1.97 1.27-3.05 0.002 – – – 2.51 1.07-5.87 0.034
Hb (g/dL) 1.07 0.99-1.16 0.078 0.91 0.82-1.03 0.125 0.78 0.60-1.00 0.108
Female Hb (g/dL) 1.28 1.09-1.51 0.003 1.29 1.09-1.54 0.003 1.51 1.06-2.18 0.024
Cr (mg/dL). 2.19 1.48 - 1.26 <0.001 – – – – – –
Cr. clear (mL/min). 0.97 0.96-0.98 <0.001 0.97 0.96-0.97 <0.001 0.95 0.94-0.97 <0.001
ALT (mmol/L) 0.99 0.99-1.00 0.349 – – – – – –
AST (mmol/L) 0.99 0.99-1.00 0.243 – – – – – –
Hep. B sAg (pos) 0.56 0.31-1.01 0.056 0.60 0.32-1.11 0.101 0.28 0.04-2.20 0.225
Hep. C (pos) 1.66 0.79-3.50 0.181 1.52 0.67-3.36 0.302 1.54 0.25-6.86 0.602
Abbreviations: ALT – Alanine transaminase; AST – Aspartate transaminase; BMI – Body Mass Index; clear. – clearance; CD4+ – Cluster of Differentiation; CI – Confidence
Interval; cp – copies; Cr. – Creatinine; IQR – Inter Quartile Range; Kg – Kilogramme; M2 – Meter; SD – Standard Deviation; WHO – World Health Organization; dL –
deciliter; g – grams; Hg – mercury; mmol – millimols; mL − milliliter; mm – millimeters; µL – microliter
* n=968 (
< 50 years n = 912; > 50 years n = 56) in log 10 copies per milliliter.
§ Baseline adjusted model; Ω - model with viral load, interaction between gender and hemoglobin; and creatinine clearance (BMI excluded)
α − WHO stages 2, 3 & 4 included as a linear trend
doi: 10.1371/journal.pone.0076158.t002
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compared to the non–HIV infected population [36,37]. Thus,
older adults infected with HIV may require even closer
monitoring of their renal and cardiovascular function, bearing in
mind resultant poly-pharmacy and excess burden to the organs
in the event of co-administration of treatment.
Although older adults had statistically higher CD4+ cell
counts and higher plasma HIV–1 RNA levels compared to
younger adults, clinically this should be interpreted cautiously.
Coupled with the finding of fewer older adults in the lower WHO
stages 3 and 4 univariate analysis, the higher CD4 counts
suggests either earlier presentation and access to HIV care by
older adults, or that more older adults died before they could
access care, leaving those survivors who joined the DART trial
with better underlying prognosis. The higher viral loads in older
persons would tend to support the latter explanation, although
they could also reflect decreased ability of the older immune
system to respond to HIV [38].
This study had limitations, which can be addressed by future
research. Relatively few older adults were recruited in the
DART trial meaning power to detect differences between older
and younger adults was low. In addition viral load results were
available for only a third of the participants, thus limiting power
of the findings in the second model. Certain data were not
collected including substance abuse, mental health as well as
specific biomarkers such as cholesterol, D–dimer, cystatin C
and IL–6 all of which have been found to predict HIV treatment
outcomes among older adults in western cohorts [39,40].
Lastly, a control group of non–HIV infected individuals would
have provided vital information on the effect of HIV infection
itself. Nonetheless, this is among the first studies on HIV and
aging to explore clinical and immunological differences in a
sub–Saharan African cohort.
Conclusions
Our study explored and identified some bio-markers which
may be useful in optimizing monitoring of care for older adults
with HIV and AIDS. We also exposed information gaps for
future research in cohorts of older adult Africans with HIV.
These include establishing non–HIV infected cohorts to
compare whether indeed in this setting, there is an interaction
between aging and HIV in the clinical, immunological
differences identified in our study; and which of these are
optimal for reliably predicting outcomes of HIV treatment.
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